A nurse is reinforcing teaching about the purpose of quadruple screening for a client who is at 16 weeks of gestation. Which of the following statements should the nurse make?

A. Position the seat of the wheelchair at a right angle to the bed: Proper wheelchair positioning is important to facilitate a safe pivot transfer and reduce the distance the client must move. However, ensuring environmental safety by stabilizing equipment must occur before positioning. The wheelchair can be placed correctly after confirming both surfaces are secure.

B. Lock the wheels on the bed: Safety is the priority before initiating any transfer. Locking the wheels on the bed prevents unintended movement that could result in loss of balance or falls, particularly in a client with unilateral weakness. Stabilizing the bed establishes a secure foundation prior to assisting the client to sit or stand.

C. Have the client sit at the edge of the bed: Dangling at the bedside allows assessment for orthostatic hypotension and balance, but this step should occur only after ensuring the bed is secure. Assisting the client to sit before locking the wheels increases fall risk if the bed shifts.

D. Place a gait belt around the client's waist: A gait belt enhances stability and control during transfer, especially for a client with left-sided weakness. However, it is applied after environmental safety measures, such as locking the bed and wheelchair, are completed.

A. Insulin lispro: Lispro is a rapid-acting insulin that can be mixed with intermediate-acting insulins such as NPH in the same syringe. When mixing, lispro is drawn into the syringe first to maintain its rapid-acting properties and prevent contamination of the intermediate insulin.

B. Insulin aspart: Aspart is another rapid-acting insulin compatible with intermediate-acting insulins like NPH for mixing. Proper technique involves drawing the rapid-acting insulin first, ensuring stable blood glucose control while reducing the number of injections.

C. Regular insulin: Regular insulin is short-acting and can be mixed with NPH insulin. This combination allows for both immediate and intermediate glycemic control, making it convenient for clients requiring multiple insulin actions in a single injection.

D. Insulin glargine: Glargine is a long-acting insulin that forms microprecipitates in subcutaneous tissue for steady absorption. It cannot be mixed with other insulins because mixing alters its pharmacokinetics and can compromise its peakless effect.

E. Insulin detemir: Detemir is also a long-acting insulin and must be administered separately. Mixing it with other insulins can change absorption rates and efficacy, making it unsafe to combine in the same syringe.